Drug Trial Radar · NCT04306224
A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas
Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Jun 5, 2020
Primary completion
Oct 7, 2022
Study completion Oct 7, 2022
Sponsor
- Lead sponsor
- ImmuneOncia Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 12, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is the first-in-human, Phase I, open-label, multiple-ascending dose study to investigate the safety, tolerability, PK, PharmDyn, and clinical activity of IMC-002 in subjects with metastatic or locally advanced solid tumors and relapsed or refractory lymphomas. Male or female subjects 18 years and older with metastatic or locally advanced solid tumors and relapsed or refractory lymphomas will be included in the study if they meet all the inclusion criteria and none of the exclusion criteria. The study will consist of 2 parts: Part 1: Dose Escalation Part 2: Expansion Cohorts
Conditions
- Solid Tumor
- Lymphoma
Interventions
IMC-002Biological
IMC-002 blocks the interaction between CD47 and SIRPα.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of dose-limiting toxicities (DLT)Time frame: For 28 days
- Incidence and severity of adverse events (AEs)Time frame: 2 years
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
Washington University School of Medicine - Siteman Cancer Center
St Louis, Missouri
The University of Texas MD Anderson Cancer Center
Houston, Texas
NEXT Oncology
San Antonio, Texas
Seoul National University Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.